{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T21:56:43Z","timestamp":1777586203606,"version":"3.51.4"},"reference-count":25,"publisher":"SAGE Publications","issue":"5-6","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Eur J Mass Spectrom (Chichester)"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>\n                    Naltrexone, an FDA-approved mu-opioid receptor antagonist for alcohol dependence, requires therapeutic drug monitoring due to its pharmacokinetic variability. This study developed a liquid chromatography-electrospray ionization-tandem mass spectrometry method for accurately quantifying naltrexone and its active metabolite, 6\u03b2-naltrexol, using deuterated internal standards (naltrexone-d\n                    <jats:sub>3<\/jats:sub>\n                    and 6\u03b2-naltrexol-d\n                    <jats:sub>3<\/jats:sub>\n                    ). Sample preparation involved solid-phase extraction with a Strata-X cartridge followed by elution. Separation was performed on a C18 column with gradient elution at 0.3\u2005mL\/min. Detection in dynamic multiple reaction monitoring mode used ion transitions at m\/z 342\u2009&gt;\u2009324 for naltrexone and m\/z 344\u2009&gt;\u2009161 for 6\u03b2-naltrexol. The calibration curves were linear over the range of 0.0152\u201333.3\u2005ng\/mL for naltrexone and 0.410\u2013100. ng\/mL for 6\u03b2-naltrexol, both with a correlation coefficient of 1.0000 and 0.9998, individually. Intraday and interday variations were below 9.2% for naltrexone and 6.6% for 6\u03b2-naltrexol. The recovery was 99.5% for naltrexone and 95.0% for 6\u03b2-naltrexol. Applied to plasma samples from five patients receiving 50\u2005mg oral naltrexone daily for 12 weeks, average concentrations were 3.30\u2009\u00b1\u20094.40\u2005ng\/mL (naltrexone) and 48.5\u2009\u00b1\u200923.4\u2005ng\/mL (6\u03b2-naltrexol). The developed assay method effectively quantifies naltrexone and its metabolite in alcohol-dependent patients in Taiwan.\n                  <\/jats:p>","DOI":"10.1177\/14690667251384047","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T18:28:42Z","timestamp":1759516122000},"page":"161-168","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of a liquid chromatography-tandem mass spectrometry method for the analysis of plasma naltrexone and its active metabolite in patients with AUD"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4556-1648","authenticated-orcid":false,"given":"Po-Tsun","family":"Shen","sequence":"first","affiliation":[{"name":"National Health Research Institutes"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu Chih","family":"Liu","sequence":"additional","affiliation":[{"name":"Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli County, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chyi","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Addiction Sciences, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan"},{"name":"Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"},{"name":"Psychiatric Research Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan"},{"name":"Psychiatric Research Center, Taipei Medical University Hospital, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Li","family":"Liu","sequence":"additional","affiliation":[{"name":"Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli County, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"e_1_3_2_2_2","unstructured":"WHO. Global Status Report on Alcohol and Health. 2018."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(19)30231-2"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2019.106128"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.0584"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.86"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2009.24.1.1"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20230488"},{"key":"e_1_3_2_9_2","first-page":"37","article-title":"Naltrexone in the treatment of alcohol addiction","volume":"28","author":"Ochoa E","year":"2000","unstructured":"Ochoa E. Naltrexone in the treatment of alcohol addiction. Actas Esp Psiquiatr 2000; 28: 37\u201343.","journal-title":"Actas Esp Psiquiatr"},{"key":"e_1_3_2_10_2","first-page":"51","article-title":"Naltrexone in the treatment of alcohol dependence","volume":"26","author":"Ochoa Mangado E","year":"1998","unstructured":"Ochoa Mangado E. Naltrexone in the treatment of alcohol dependence. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1998; 26: 51\u201357.","journal-title":"Actas Luso Esp Neurol Psiquiatr Cienc Afines"},{"key":"e_1_3_2_11_2","unstructured":"Singh D Saadabadi A. Naltrexone. In StatPearls Treasure Island (FL) 2025."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/13556210500223504"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.767506"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-9556(25)05648-X"},{"key":"e_1_3_2_15_2","first-page":"15","article-title":"Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration","volume":"45","author":"Meyer MC","year":"1984","unstructured":"Meyer MC, Straughn AB, Lo MW, et al. Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J Clin Psychiatry 1984; 45: 15\u201319.","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agy067"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2025.116944"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-5-439"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/21.4.252"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/31.8.453"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2006.07.035"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2015.06.028"},{"key":"e_1_3_2_23_2","unstructured":"MarvinSketch. Calculation module developed by ChemAxon http:\/\/www.chemaxon.com\/products\/marvin\/marvinsketch\/). Version 24.3.2 (2024."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2025.116711"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.2174\/0113892010271975231218074830"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2015.04.044"}],"container-title":["European Journal of Mass Spectrometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/14690667251384047","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/14690667251384047","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/14690667251384047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T20:04:44Z","timestamp":1777406684000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/14690667251384047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":25,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/14690667251384047"],"URL":"https:\/\/doi.org\/10.1177\/14690667251384047","relation":{},"ISSN":["1469-0667","1751-6838"],"issn-type":[{"value":"1469-0667","type":"print"},{"value":"1751-6838","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}